InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,099.96
(
1.02%
)
US TECH 100
17,239.20
(
1.54%
)
Dow Jones
38,239.66
(
0.40%
)
Brent Oil
88.17
(
0.02%
)
Bitcoin
63,977.08
(
-0.79%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Jesspro

Send PM Follow Ignore
Followers 41
Posts 6066
Boards Moderated 1
Alias Born 06/29/2011

Jesspro

Re: None

Sunday, 10/04/2015 7:53:06 PM

Sunday, October 04, 2015 7:53:06 PM

Post# of 80490


Chemotherapy plus PON: a new standard for Ph-positive ALL?

"Chemotherapy plus PON: a new standard for Ph-positive ALL?" an editorial by Thomas X in this week's Lancet Oncology. Editorial is a companion to the report from MD Anderson reporting 2 year event free survival of 82% in phase 2 trial. PON results superior to DAS, NIL and IMA in literature. 10 years ago median survival in Ph+ ALL was less than 1 yr.

With Incidence of Ph+ ALL in US of 2,000/yr and median survival beyond 2 yrs PON target population would be in the order of 5,000/yr in the US.

posted by mulanoom
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up